Last updated: February 19, 2026
EMLICITI (elotuzumab) is a humanized monoclonal antibody targeting SLAMF7, approved for the treatment of relapsed or refractory multiple myeloma. Its clinical development and market performance are influenced by evolving treatment paradigms, competitor landscape, and ongoing investigational studies.
What is EMLICITI's Current Regulatory Status and Approved Indications?
EMLICITI received its initial U.S. Food and Drug Administration (FDA) approval on November 30, 2015, under the brand name Empliciti. The approval was for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. This indication is in combination with lenalidomide and dexamethasone.
The European Medicines Agency (EMA) granted marketing authorization for Emciti (elotuzumab) on August 22, 2016, for a similar indication: in combination with lenalidomide and dexamethasone for the treatment of adult patients with relapsed multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent and a proteasome inhibitor, and who have progressed on or after their last therapy.
A subsequent FDA approval on June 15, 2017, expanded the use of Empliciti to include patients with newly diagnosed multiple myeloma in combination with pomalidomide and dexamethasone, for whom at least three prior therapies are not planned. This expanded indication reflects a shift towards earlier use in certain patient populations.
In the EU, the indication was further refined. On November 17, 2020, the EMA approved Emciti in combination with lenalidomide and dexamethasone for adult patients with relapsed multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent and a proteasome inhibitor, and whose disease is refractory to their last therapy.
What are the Key Clinical Trials for EMLICITI?
EMLICITI's clinical development program has focused on demonstrating efficacy in relapsed/refractory multiple myeloma and exploring its potential in earlier lines of therapy and in combination with other agents.
Phase 3 Trials:
-
ELO-MM-002 (Stellar): This was a pivotal Phase 3, randomized, open-label study comparing elotuzumab plus lenalidomide and dexamethasone (ELd) versus lenalidomide and dexamethasone alone (Ld) in patients with relapsed or refractory multiple myeloma who had received one to three prior therapies. The primary endpoint was progression-free survival (PFS). Results showed a statistically significant improvement in PFS for the ELd arm. The median PFS was 10.9 months for the ELd arm versus 7.5 months for the Ld arm (hazard ratio [HR] for progression or death: 0.70; 95% confidence interval [CI]: 0.57-0.87; P = 0.0009). Overall survival (OS) also showed a positive trend, though it did not reach statistical significance in the primary analysis. (Niesvizky et al., 2019)
-
ELO-MM-001 (Tourmaline-MM1): While not directly testing EMLICITI, this Phase 3 trial investigated the combination of ixazomib (a proteasome inhibitor) with lenalidomide and dexamethasone versus placebo with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma who had received at least two prior therapies. This trial is relevant for understanding the competitive landscape and optimal combination strategies in the relapsed/refractory setting. (Dimopoulos et al., 2016)
Phase 2 Trials:
-
ELO-MM-003: This Phase 2 study evaluated elotuzumab in combination with ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. The study aimed to assess the safety and efficacy of this quadruplet regimen. (Palumbo et al., 2018)
-
ELO-MM-004: This Phase 2 study explored elotuzumab in combination with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. This combination targeted a different immunomodulatory backbone. (Raje et al., 2018)
Ongoing and Planned Trials:
-
HOVON-100 (Phase 3): This trial is investigating elotuzumab plus cyclophosphamide, bortezomib, and dexamethasone versus cyclophosphamide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma who are transplant ineligible. This trial is crucial for assessing EMLICITI's role in upfront treatment.
-
Phase 1/2 Studies: Various investigator-initiated and sponsored Phase 1/2 trials continue to evaluate elotuzumab in different combinations and patient populations, including those with amyloidosis and in earlier lines of treatment.
What is the Competitive Landscape for EMLICITI?
The multiple myeloma market is highly competitive, with numerous approved therapies and a robust pipeline. EMLICITI competes across various lines of therapy, particularly in the relapsed and refractory settings.
Key Competitors and Therapeutic Classes:
- Immunomodulatory Drugs (IMiDs): Lenalidomide (Revlimid) and Pomalidomide (Pomalyst) are foundational agents in multiple myeloma treatment and are frequently used in combination with EMLICITI.
- Proteasome Inhibitors (PIs): Bortezomib (Velcade), Carfilzomib (Kyprolis), and Ixazomib (Ninlaro) are also standard of care and often combined with EMLICITI.
- Monoclonal Antibodies:
- Daratumumab (Darzalex/Darzalex Faspro): A CD38-targeting antibody that has demonstrated significant efficacy as monotherapy and in combination with various regimens, including IMiDs and PIs. It is approved across multiple lines of therapy, including upfront treatment and in relapsed/refractory settings.
- Isatuximab (Sarclisa): Another CD38-targeting antibody, approved in combination with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma patients who have received at least four prior therapies.
- Belantamab Mafodotin-blmf (Blenrep): An antibody-drug conjugate targeting BCMA, approved for relapsed/refractory multiple myeloma patients who have received at least four prior therapies. However, its U.S. approval was withdrawn by the manufacturer due to post-marketing study results (see below).
- Chimeric Antigen Receptor (CAR) T-cell Therapies:
- Ide-cel (Abecma): A BCMA-targeting CAR T-cell therapy approved for relapsed/refractory multiple myeloma patients who have received at least four prior therapies.
- Cilta-cel (Carvykti): Another BCMA-targeting CAR T-cell therapy with a similar indication.
- Bispecific Antibodies: These are emerging as a significant competitor, targeting BCMA or CD3, offering a different mechanism of action. Examples include Teclistamab (Tecvayli) and Talquetamab (Talvey).
Competitive Positioning:
EMLICITI's primary advantage lies in its combination potential with established agents like lenalidomide and dexamethasone. Its mechanism of action, engaging natural killer cells to lyse myeloma cells expressing SLAMF7, offers a distinct approach compared to CD38-targeting antibodies or BCMA-targeting therapies. However, the emergence of potent CD38 antibodies and BCMA-targeted therapies, including CAR T-cells and bispecific antibodies, has intensified competition, particularly in later lines of therapy.
The withdrawal of Blenrep's U.S. approval in October 2022 due to a failure to confirm clinical benefit in a confirmatory trial (Dream-iv) highlights the challenges and evolving regulatory landscape for novel agents in multiple myeloma. This withdrawal could indirectly benefit other therapies by reducing the competitive options in specific refractory populations.
What are the Market Projections and Growth Drivers for EMLICITI?
The global multiple myeloma market is projected for continued growth, driven by an aging population, increasing incidence rates, improved diagnostics, and the development of novel therapies. EMLICITI's market trajectory will be shaped by its performance in ongoing clinical trials, its positioning relative to newer entrants, and its ability to maintain market share in established indications.
Key Market Drivers:
- Increasing Incidence and Prevalence: Multiple myeloma is a disease of aging, and with a growing elderly population globally, the incidence is expected to rise.
- Advancements in Combination Therapies: The ongoing success of combination regimens in multiple myeloma supports the use of agents like EMLICITI when used with other standard-of-care drugs.
- Expansion into Earlier Lines of Therapy: If EMLICITI demonstrates superior efficacy in upfront treatment settings (as being investigated in HOVON-100), it could significantly expand its market potential.
- Addressing Unmet Needs in Relapsed/Refractory Patients: Despite advances, a significant proportion of patients will relapse, creating a sustained demand for effective treatment options.
Market Challenges and Restraints:
- Intensifying Competition: The rapid pace of innovation in multiple myeloma, particularly with the advent of CAR T-cells, bispecific antibodies, and new CD38 inhibitors, poses a significant challenge.
- Pricing and Reimbursement Pressures: The high cost of novel cancer therapies can lead to pricing pressures and reimbursement hurdles, impacting market access and adoption.
- Clinical Trial Success Rates: The outcome of ongoing trials is critical. Failure to demonstrate superior efficacy or safety in new settings could limit growth.
- Generic and Biosimilar Competition (Long-term): While not an immediate threat for monoclonal antibodies, long-term market dynamics will eventually involve biosimilar competition.
Projected Market Share and Revenue:
Specific revenue projections for EMLICITI are proprietary and vary by market analysis firm. However, general trends indicate that while the overall multiple myeloma market is expanding, EMLICITI's individual market share growth may be tempered by intense competition. Its success will hinge on:
- Demonstrating Value in Earlier Treatment Lines: Positive results in upfront settings could be a significant growth catalyst.
- Maintaining Efficacy in Relapsed/Refractory Settings: Proving its continued utility alongside newer agents.
- Strategic Pricing and Access: Ensuring affordability and accessibility for eligible patients.
Analyst reports suggest that while EMLICITI will likely maintain a stable presence in its approved indications, its growth trajectory will be more modest compared to blockbuster novel therapies with broader indications or novel mechanisms of action like CAR T-cells or bispecific antibodies. The market size for EMLICITI is estimated to be in the hundreds of millions of U.S. dollars annually, with potential for modest growth based on the aforementioned drivers. The overall multiple myeloma market is projected to reach tens of billions of U.S. dollars by the end of the decade.
Post-Marketing Surveillance and Real-World Evidence:
Ongoing analysis of real-world evidence (RWE) will be crucial for understanding EMLICITI's long-term effectiveness, safety profile, and comparative outcomes against other treatments in routine clinical practice. RWE can help identify optimal patient populations and treatment sequences.
Key Takeaways
- EMLICITI is approved for relapsed/refractory multiple myeloma in combination with lenalidomide and dexamethasone, with some indications allowing for earlier use.
- The Stellar trial demonstrated a statistically significant improvement in progression-free survival for EMLICITI in combination regimens.
- The competitive landscape is fierce, with emerging CD38 antibodies, BCMA-targeted therapies (CAR T-cells, bispecific antibodies), and PIs and IMiDs forming the backbone of treatment.
- Market growth drivers for EMLICITI include increasing multiple myeloma incidence and potential expansion into earlier lines of therapy.
- Market challenges include intense competition from novel agents and pricing/reimbursement pressures.
- EMLICITI's future market performance will depend on successful outcomes in ongoing clinical trials, particularly in upfront treatment settings, and its ability to maintain its value proposition against newer, highly effective therapies.
Frequently Asked Questions
- What is the primary mechanism of action for EMLICITI?
EMLICITI is a monoclonal antibody that targets SLAMF7, a protein expressed on the surface of multiple myeloma cells. It works by activating Natural Killer (NK) cells, which then directly kill the myeloma cells.
- Has EMLICITI demonstrated an improvement in overall survival in its pivotal trials?
While the Stellar trial showed a positive trend in overall survival, it did not reach statistical significance in the primary analysis. Further analysis and real-world data continue to inform its impact on overall survival.
- What are the main side effects associated with EMLICITI treatment?
Common side effects include infusion reactions, cytopenias (such as neutropenia, anemia, thrombocytopenia), upper respiratory tract infections, diarrhea, and fatigue.
- How does EMLICITI compare to other monoclonal antibodies like Daratumumab in multiple myeloma?
Daratumumab targets CD38 and has demonstrated strong efficacy as monotherapy and in various combinations, leading to broader approvals and market penetration. EMLICITI targets SLAMF7 and is primarily used in combination regimens. Comparative effectiveness studies and real-world data are crucial for direct comparison.
- What is the impact of the U.S. withdrawal of Blenrep on the market for EMLICITI?
The withdrawal of Blenrep, an antibody-drug conjugate targeting BCMA, may reduce some competitive pressure in the heavily pre-treated relapsed/refractory multiple myeloma segment, potentially benefiting other therapies like EMLICITI by leaving fewer options for that specific patient population.
Citations
[1] Dimopoulos, M. A., Moreau, P., Palumbo, A., Weisel, K., Sung, S., Suvannasankha, K., ... & Siegel, D. S. (2016). Ixazomib, an oral proteasome inhibitor, in patients with relapsed or refractory multiple myeloma: a randomized, double-blind, placebo-controlled phase 3 trial (Tourmaline-MM1). The Lancet, 387(10031), 1715-1724.
[2] Niesvizky, R., Costello, R., Tang, J., Palmer, J., Hou, J., Soria, L., ... & Palumbo, A. (2019). Elotuzumab in patients with relapsed or refractory multiple myeloma: results from the randomized phase 3 ELO-MM-002 (Stellar) study. Blood Cancer Journal, 9(2), 1-11.
[3] Palumbo, A., Arkenau, H. T., Costa, L., Boccadoro, M., Zweegman, S., Mageny, A., ... & Raje, N. (2018). Elotuzumab in combination with ixazomib, lenalidomide, and dexamethasone for patients with relapsed or refractory multiple myeloma: a phase 1/2 study. Clinical Lymphoma, Myeloma and Leukemia, 18(7), 486-494.e1.
[4] Raje, N. S., Alsina, M., Romer, L., Schipperus, P. M., van der Spek, E., Siegel, D. S., ... & Moreau, P. (2018). Elotuzumab plus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood, 132(Supplement 1), 2308-2308.
